Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASTRO Annual Meeting
Hypofractionated Radiation May Be New Treatment Paradigm in Patients Unable to Receive Standard of Care
By
Phoebe Starr
ASTRO Annual Meeting
October 2016, Vol 7, No 9
Read Article
Newer, More Costly Radiation Technologies Adopted in Elderly Patients with Breast Cancer
By
Phoebe Starr
ASTRO Annual Meeting
November 2012, Vol 3, No 8
In a study of patients who were enrolled in the Surveillance, Epidemiology and End Results–Medicare database, these utilization patterns led to a cost increase of 63% per patient. The study’s results were reported at the 2012 American Society for Radiation Oncology annual meeting.
Read Article
Proton Beam Therapy: Similar Toxicity to Standard Radiation, at Much Higher Cost
By
Phoebe Starr
ASTRO Annual Meeting
November 2012, Vol 3, No 8
A study presented at the 2012 American Society for Radiation Oncology annual meeting found few differences in toxicity between the 2 techniques, but demonstrated that PBRT was associated with a 57% increase in median cost per patient.
Read Article
Stereotactic Body Radiation Therapy Cost-Saving, Convenient for Patients with Prostate Cancer
By
Phoebe Starr
ASTRO Annual Meeting
November 2012, Vol 3, No 8
Boston, MA—In the United States right now, intensity modulated radiation therapy (IMRT) has largely replaced 3-dimensional conformal radiation therapy as the technique of choice for most patients with organ-confined prostate cancer that is being treated with radiation as the primary therapy.
Read Article
Hypofractionated Radiotherapy in Prostate Cancer More Convenient for Patients
By
Phoebe Starr
ASTRO Annual Meeting
December 2011, Vol 2, No 7
Delivering higher doses of external-beam radiation over a shorter period (hypofractionated radiation) was as effective as conventional radiation in preventing treatment failure in men with intermediate- to high-risk prostate cancer.
Read Article
High-Dose Radiation Does Not Improve Survival in Stage III NSCLC
By
Phoebe Starr
ASTRO Annual Meeting
December 2011, Vol 2, No 7
Read Article
Reporting Gap for Near-Misses and Errors in Radiation Oncology Is Rampant
By
Phoebe Starr
ASTRO Annual Meeting
December 2011, Vol 2, No 7
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma